Hepion Pharmaceuticals, Inc. dismissed Grassi & Co., CPAs, P.C. as its independent registered public accounting firm and engaged Rosenberg Rich Baker Berman P.A. (RRBB) effective September 21, 2026. The prior auditor's reports on fiscal years ended December 31, 2025 and 2024 contained an explanatory paragraph noting substantial doubt regarding the company's ability to continue as a going concern due to significant operating losses and negative cash flows. There were no reportable events or disagreements with Grassi on accounting principles, financial statement disclosures, or auditing scope. Hepion Pharmaceuticals operates in the biotechnology industry, focusing on drug discovery and development.
